Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension. 1980

T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen

The haemodynamic effects of labetalol were studied in patients with essential hypertension after acute and long-term administration. In the acute study 50 mg of labetalol was given i.v. to 10 patients. Eight of them were re-examined after three to four months of oral treatment with labetalol 300 mg t.i.d. Measurements were made at supine rest, after five minutes in the upright position, and after five minutes' supine bicycle exercise at 50 and 100 watt work loads. In the acute study cardiac output was unchanged except at the work load of 100 watt when it decreased 18%. The mean blood pressure decreased under all conditions, 11.6 mm Hg at supine rest, 22.3 mm Hg in the upright position and 15.9 mm Hg and 16.9 mm Hg at the two work loads. Heart rate was unchanged at supine rest, and reduced by 10% in the other situations. Total peripheral resistance was reduced significantly at rest in the supine and upright positions, but not during exercise. Pulmonary artery pressure was unchanged. In the long-term study cardiac output was unchanged except of the heavy work load when it decreased 11%. Mean blood pressure was reduced significantly by 14.6 mm Hg at supine rest, 16.8 mm Hg in the upright position and by 13.9 mm Hg and 13.4 mm Hg, respectively, at the two work loads. Heart rate was reduced significantly in all conditions by 10-14%. Total peripheral resistance decreased significantly at rest, but not during exercise, and pulmonary artery pressure was unchanged.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007741 Labetalol A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. AH-5158,Albetol,Apo-Labetalol,Dilevalol,Labetalol Hydrochloride,Labetalol, (R,R)-Isomer,Labetolol,Normodyne,Presolol,R,R-Labetalol,SCH-19927,Trandate,AH 5158,AH5158,Apo Labetalol,ApoLabetalol,Hydrochloride, Labetalol,R,R Labetalol,SCH 19927,SCH19927
D008297 Male Males
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
August 1983, Journal of hypertension,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
February 1992, European heart journal,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
August 1989, Journal of hypertension,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
June 1991, European heart journal,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
January 1991, Postgraduate medical journal,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
April 1977, British journal of clinical pharmacology,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
January 1984, Scandinavian journal of urology and nephrology. Supplementum,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
January 1977, Postgraduate medical journal,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
July 1984, Scandinavian journal of urology and nephrology,
T L Svendsen, and S Rasmussen, and O J Hartling, and P E Nielsen, and J Trap-Jensen
December 1990, Journal of hypertension,
Copied contents to your clipboard!